What's Going On With Cadrenal Therapeutics Stock Today

什麼是怎麼回事與腎腎上治療股票今天

Benzinga Real-time News · 2023/01/24 00:41

The FDA has granted a Fast Track designation to Cadrenal Therapeutics Inc's (NASDAQ:CVKD) tecarfarin for the prevention of systemic thromboembolism, more commonly referred to as blood clots, of cardiac origin in patients with end-stage renal disease (ESRD) and atrial fibrillation (AFib).
Fast Track is a process designed to facilitate the development and expediting of the review of drugs to treat serious conditions. Fast Track aims to get important new drugs to the patient earlier.
The FDA had previously granted an Orphan Drug Designation (ODD) for tecarfarin. The FDA grants orphan status to drugs targeting rare diseases or disorders that affect fewer than 200,000 people in the U.S.
The ODD program provides certain benefits and incentives, including seven years of U.S. marketing exclusivity, waiver of FDA user fees, and tax credits for clinical research.
Tecarfarin is a Vitamin K antagonist oral anticoagulant designed to target a different pathway than the most commonly prescribed drugs used to treat thrombosis and AFib. Tecarfarin has been evaluated in eleven human clinical trials and more than 1,000 individuals.
The stock went up by 44% today and has been volatile and given up gains since.
Price Action: CVKD shares are up 0.61% at $4.15 on the last check Monday.

FDA 已授予快速通道指定給 腎上腺治療公司 (NASDAQ: CVKD) 替卡法林用於預防全身血栓栓塞, 通常被稱為血栓, 心臟起源患者的末期腎臟疾病 (ESRD) 和心房顫動 (AFIB).
快速通道是一個過程，旨在促進開發和加快藥物的審查，以治療嚴重的條件.快速通道旨在更早地向患者提供重要的新藥。
FDA 先前已授予替卡法林的孤兒藥物名稱（ODD）。FDA 對針對美國少於 200,000 人的罕見疾病或疾病的藥物授予孤兒狀態。
ODD 計畫提供特定優惠和獎勵措施，包括七年的美國行銷專屬性、豁免 FDA 使用者費用，以及臨床研究的稅收抵免。
Tecarfarin 是一種維生素 K 拮抗劑口服抗凝劑，旨在針對與用於治療血栓形成和 AFIB 的最常用處方藥物不同的途徑。他卡法林已經在十一項人體臨床試驗和 1,000 多個人中進行了評估。
股票今天上漲了 44％，並且一直在波動並放棄了收益。
價格行動： 在星期一上次檢查中，CVKD 股價上漲了 0.61%，至 4.15 美元。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。

風險及免責聲明